API Kings: Divi's, Laurus & Neuland Battle

India relies on China for 65-70% of APIs, risking supplies as seen in Covid. Government boosts local makers like Divi's Labs, Laurus Labs, and Neuland Labs. These supply global pharma, cutting China dependence and lifting shareholder value via steady orders.

s tops as API leader for 10 generics, partnering 12 of top 20 Big Pharma in 100+ nations. FY25 revenue: Rs 9,360 cr (+19%), profit Rs 2,191 cr (+37%). Q2FY26: sales Rs 2,715 cr (+16%), profit Rs 689 cr (+35%). ROE 15.4%, P/E 69—fair for debt-free, 20% ROCE firm. Reliable anti-cancer, cardio growth plus 2026-27 patent cliffs aid shareholders. Yearly 10% stock rise rewards steady holders. shines in antiretrovirals, oncology, cardio; generics Rs 4,020 cr FY25. Revenue Rs 5,554 cr (+10%), profit Rs 358 cr (+122%). Q2FY26: revenue Rs 1,654 cr (+35%), API +11%, profit Rs 195 cr (+883%). ROE 8.3%, P/E 80+ bets on growth. CDMO shifts add volatility for short-termers, but expansion promises long gains. Low promoter stake cautions, yet execution aids holders. Neuland specializes in peptides, small molecules; 1,174 KL capacity. CMS (API) 43% of FY25 Rs 1,477 cr revenue (-5%), profit Rs 260 cr (-13%). Q2FY26: revenue Rs 514 cr (+65%), CMS 60%, profit Rs 97 cr (+200%), later 166% to Rs 129 cr. P/E 100+, ROE 14.8% shows niche edge. High prices challenge, but agile ops win amid China curbs. Company P/E ROE% FY25 Profit Shareholder Fit Divi's 69 15.4 +37% Stable, conservative Laurus 80+ 8.3 +122% Growth, volatile Neuland 100+ 14.8 -13%(+Q2) Niche upside High P/Es need watch, but API push favors long-term holders. Divi's for reliability; others for bold plays on global shifts.